Rate My Professor Doan Ngo

Professor Doan Ngo is an academic pharmacist and translational scientist at the University of Newcastle's School of Biomedical Sciences and Pharmacy in the College of Health, Medicine and Wellbeing. She earned her Doctor of Philosophy in Medicine from the University of Adelaide in 2008, where she developed an animal model of aortic stenosis and demonstrated prevention with ACE inhibitors. She also holds a Bachelor of Pharmacy from the University of South Australia and a Bachelor of Health Science (Honours) from the University of Adelaide. Her research specializations include cardiometabolic pathophysiology focusing on obesity, redox stress, vascular biology, adipose tissue biology, angiogenesis, mitochondria, and their impacts on heart failure from obesity and diabetes. Ngo investigates mechanisms of cancer therapy-mediated cardiotoxicity, novel biomarkers for early heart disease detection, factors in aortic valve disease, and cardioprotective therapies during cancer treatment. As Co-director of the Newcastle Centre of Excellence in Cardio-Oncology, she advances clinical and translational programs evaluating treatments for obesity, heart failure, and chemotherapy-induced cardiotoxicity.

Ngo completed two years of postdoctoral training in Boston and three years specializing in obesity and adipose tissue biology before establishing an independent research group in Adelaide in June 2015. In July 2017, she joined the University of Newcastle as Associate Professor and later advanced to Professor, also serving on the Faculty Board as a school representative. Her achievements include the National Heart Foundation Future Leader Fellowship (2021-2025), NSW Ministry of Health EMC Fellowship ($582,000, 2018-2021), Hospital Research Foundation Mid-Career Fellowship (2015-2018), Diabetes Australia Research Trust grant (2016-2018), Heart Foundation Vanguard Grant (2016-2018), and Rebecca L Cooper Foundation Grant (2016-2017). Key publications feature 'Oxidative Stress in Heart Failure' (2020, chapter with Sverdlov AL, Colucci WS), 'From signal to care: Artificial intelligence in Cardio-oncology' (2026), 'Anti-cancer agent Olaparib ameliorates doxorubicin-induced cardiotoxicity in vitro and in vivo' (2025), and 'Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities' (2025). Her contributions significantly influence cardio-oncology through leadership in research programs and collaborations enhancing cardiovascular outcomes in cancer patients.